We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”) (NASDAQ: DFFN) in connection with its merger with EIP Pharma Inc. (“EIP Pharma”).  Under the merger agreement, EIP Pharma will merge with a newly created subsidiary of Diffusion.  Upon completion of the transaction, EIP Pharma shareholders will own 77.25% while Diffusion shareholders will only own 22.75% of the combined company.

Weiss Law is investigating whether (i) Diffusion’s board acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.